Efficacy and safety of MMFS-01, a synapse density enhancer, for treating cognitive impairment in older adults: a randomized, double-blind, placebo-controlled trial
Manuscript Number:
15-0538R2
Author(s):
Guosong Liu, Zhong-Lin Lu, Safa Sadeghpour, Jason G. Weinger, Feng Xue
Disclosures
Guosong Liu
Equity:
I am founder of Neurocentria and own some stocks of Neurocentria.
Sponsors:
I am CSO of Neurocentria, the company who sponsor the study.
Patents/Royalties
I am co-inventor of the patents the lead to development of MMFS-1 used in the current study.
Zhong-Lin Lu
Nothing to Disclose
Safa Sadeghpour
Consulting Fees:
Employee of Neurocentria, Inc.
Equity:
Hold equity in Neurocentria, Inc.
Sponsors:
Employee of Neurocentria, Inc.
Jason G. Weinger
Equity:
As an employee of Neurocentria, I receive a small amount of stock options.
Sponsors:
I am the Manager of Scientific Operations, for R&D and drug development